Dermata Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
DRMA$0.76+0.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| (unaudited) | ||
| Assets: | ||
| Cash and cash equivalents | $4,412,764 | $7,521,978 |
| Prepaid expenses and other current assets | 593,604 | 341,848 |
| Inventories | 149,734 | - |
| Total current assets | 5,156,102 | 7,863,826 |
| Property and equipment | 129,367 | - |
| Other assets | 35,330 | - |
| Total assets | $5,320,799 | $7,863,826 |
| Liabilities and Stockholders’ Equity: | ||
| Liabilities: | ||
| Accounts payable (including related party amounts of $137,491 and $86,250, respectively) | $1,119,718 | $460,811 |
| Accrued and other current liabilities (including related party amounts of $0 and $25,000, respectively) | 713,361 | 1,179,635 |
| Total liabilities | 1,833,079 | 1,640,446 |
| Commitments and Contingencies (see Note 6) | ||
| Stockholders’ Equity: | ||
| Common Stock, par value $0.0001, 250,000,000 shares authorized; 4,022,143 shares issued and outstanding as of June 30, 2026; 2,660,110 shares issued and outstanding as of December 31, 2025. | 402 | 266 |
| Additional paid-in capital | 81,535,983 | 79,457,010 |
| Accumulated deficit | (78,048,665) | (73,233,896) |
| Total stockholders’ equity | 3,487,720 | 6,223,380 |
| Total liabilities and stockholders’ equity | $5,320,799 | $7,863,826 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.